Vimarsana
Biggest News Aggregation in the World

Page 31 - Hematologic Malignancies News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Hematologic Malignancies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Hematologic Malignancies Today - Breaking & Trending Today

Sequencing, Sustainability Are Hot Topics in CAR T- and Gene Cell Therapies Discussion - Vimarsana News

Sequencing, Sustainability Are Hot Topics in CAR T- and Gene Cell Therapies Discussion

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Source: ajmc.com
Acute leukemia: Menin-targeting drug revumenib aids remission in trial - Vimarsana News

Acute leukemia: Menin-targeting drug revumenib aids remission in trial

A treatment called revumenib, which inhibits the protein menin, showed promising results for individuals with acute leukemia, and aided remission in 30% of study participants.

T-cell Therapy Global Market Report 2023: Rising Global - Vimarsana News

T-cell Therapy Global Market Report 2023: Rising Global

Dublin, March 13, 2023 (GLOBE NEWSWIRE) -- The "T-cell Therapy Market Size, Share & Trends Analysis Report By Modality, By Therapy (CAR T-cell,...

Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia - Vimarsana News

Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia

- Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical...

Orca Bio Presents Positive Data Reinforcing Clinical Profile of Orca-T and Orca-Q at 2023 Transplant - Vimarsana News

Orca Bio Presents Positive Data Reinforcing Clinical Profile of Orca-T and Orca-Q at 2023 Transplant

– Three oral presentations showcase clinical evidence for Orca Bio’s promising pipeline of early- and late-stage high-precision cell therapies –– Orca-T demonstrated high relapse-free survival in recipients with fully matched donors and early potential in patients with mismatched donors –– Orca-Q showed improved gra...